Surely it did not take this long to come to this conclusion...
Q1: Who's funding it?
Q2: What is the programme?
Q3: Who is funding the Ph3 FSGS?
Q4: Where is all the talk around legacy affect?
Q5: Technical folk - what do you make of the information?
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease, page-2
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.0¢ |
Change
-0.030(6.82%) |
Mkt cap ! $225.7M | |||
| Open | High | Low | Value | Volume |
| 43.0¢ | 44.0¢ | 41.0¢ | $516.3K | 1.216M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 64574 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 48584 | 3 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |